Catalyst Pharmaceuticals (CPRX) Invested Capital (2010 - 2026)

Catalyst Pharmaceuticals has reported Invested Capital for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 27.5% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 27.5% YoY), and the FY2025 full-year result was $954.3 million, up 31.15% from the prior year.
• Invested Capital for Q1 2026 stood at $1.0 billion, up from $954.3 million in the prior quarter.
• The five-year high for Invested Capital was $1.0 billion in Q1 2026, with the low at $220.2 million in Q1 2022.
• Historically, Invested Capital has averaged $563.1 million across 5 years, with a median of $561.4 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital grew 23.27% — and 2024, when it surged 89.63%.
• Catalyst Pharmaceuticals' Invested Capital stood at $300.4 million in 2022, then increased by 29.11% to $387.9 million in 2023, then jumped by 87.59% to $727.6 million in 2024, then soared by 31.15% to $954.3 million in 2025, then advanced by 6.12% to $1.0 billion in 2026.
• The last three Invested Capital figures came in at $1.0 billion (Q1 2026), $954.3 million (Q4 2025), and $920.2 million (Q3 2025), per Business Quant data.